Protalix Biotherapeutics (PLX) 2.23 $PLX Hot Stock:

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 1:19 PM

Protalix Biotherapeutics (PLX) 2.23 $PLX

Hot Stock: Protalix BioTherapeutics, Shares Gain 5.3% (PLX)
Comtex SmarTrend(R) - Thu Apr 23, 10:52AM CDT
Protalix BioTherapeutics (AMEX

LX) is one of today's best performing low-priced stocks, up 5.3% to $2.19 on 1.0x average daily volume. Protalix BioTherapeutics has traded 245,000 shares thus far today, vs. average volume of 239,000 shares per day. The stock has outperformed the Dow (5.3% to the Dow's -0.0%) and outperformed the S&P 500 (5.3% to the S&P's 0.0%) during today's trading.
PLX: 2.23 (+0.01)

Genzyme starts mid-stage trial of oral Fabry disease therapy
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 10:34AM CDT

SHPG: 255.11 (-0.26), PLX: 2.23 (+0.01), SNY: 51.75 (-0.01), FOLD: 12.25 (-0.05)

Surging Earnings Estimates Signal Good News for Protalix BioTherapeutics (PLX) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 10, 7:43AM CDT
Protalix BioTherapeutics has decent short-term momentum and it is seeing solid activity on the earnings estimate revision front as well
PLX: 2.23 (+0.01)

Protalix BioTherapeutics (PLX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 8:08AM CDT
Protalix BioTherapeutics (PLX) Shares March Higher, Can It Continue?
PLX: 2.23 (+0.01)

Why Protalix BioTherapeutics (PLX) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 7:35AM CDT
Protalix BioTherapeutics in the Biotechnology space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
PLX: 2.23 (+0.01)

Protalix BioTherapeutics (PLX): An Off-the-Radar Potential Winner - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 7:35AM CDT
One company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Protalix BioTherapeutics, the stock of which company has actually seen rising estimates over the past one month.
PLX: 2.23 (+0.01)

Amicus up 20% premarket on accelerated timelines for Europe and U.S. applications for migalastat
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 6:41AM CDT

SHPG: 255.11 (-0.26), PLX: 2.23 (+0.01), SNY: 51.75 (-0.01), FOLD: 12.25 (-0.05)

Protalix BioTherapeutics reports FY14 results
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 3:50PM CDT

PLX: 2.23 (+0.01)

Protalix BioTherapeutics Reports Full Year 2014 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Mar 12, 3:30PM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT

LX) (TASE

LX), today reported financial results for the year ended December 31, 2014 and provided an update on recent corporate developments.
PLX: 2.23 (+0.01)

Next Week In Biotech: Kythera Ad Comm, Roth Conference, Zogenix Earnings
SA Editor Mike Taylor - at Seeking Alpha - Fri Mar 06, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 9.26 (+0.05), OMED: 26.16 (+0.29), BIOA: 10.44 (-0.24), SUPN: 13.76 (-0.18), CTIC: 1.96 (+0.01), ALXA: 1.94 (-0.06), DSCI: 8.09 (-0.31), ANTH: 5.20 (+0.31), CYTX: 0.99 (+0.01), KYTH: 50.44 (-0.54), ANAC: 64.49 (-2.10), ATHX: 1.29 (-0.03), CRMD: 8.61 (-0.22), ACRX: 4.58 (-0.16), TROV: 8.80 (-0.13), ZGNX: 1.54 (-0.11), PETX: 15.86 (-0.43), RPRX: 8.43 (-0.06), IMUC: 0.53 (-0.01), PGNX: 6.03 (-0.38), SNTA: 2.69 (-0.28), BLCM: 27.88 (-0.46), TXMD: 7.12 (-0.12), OGXI: 2.19 (+0.04), AST: 14.77 (+0.66), PLX: 2.23 (+0.01), ATRS: 2.72 (-0.04)

Protalix Bio up on positive interim data for Fabry disease candidate
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 8:27AM CST

PLX: 2.23 (+0.01)

Protalix BioTherapeutics Presents Additional Positive Phase I/II Interim Clinical Data on PRX-102 for Fabry Disease at the WORLD Symposium
GlobeNewswire - Thu Feb 12, 6:36AM CST
New Positive Clinical Data on Cardiac and Kidney Functions
PLX: 2.23 (+0.01)

Protalix Finishes Patient Enrollment for Fabry Disease Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 3:39PM CST
Protalix (PLX) completed patient enrolment in a phase I/II study on its Fabry disease candidate PRX-102.
SHPG: 255.11 (-0.26), OPHT: 52.15 (+0.17), PLX: 2.23 (+0.01), SNY: 51.75 (-0.01)

Protalix BioTherapeutics Completes Enrollment in Phase I/II Clinical Trial of PRX-102 for Fabry Disease
GlobeNewswire - Mon Feb 02, 6:00AM CST
Protalix BioTherapeutics, Inc. (NYSE MKT

LX) (TASE

LX), announced today that the Company has completed enrollment in its phase I/II clinical trial of PRX-102 for the treatment of Fabry disease. All patients that completed the trial have opted to continue to receive PRX-102 in an open-label extension trial. PRX-102 is a proprietary plant cell-expressed, chemically modified recombinant alpha-galactosidase-A enzyme that is designed to be a more stable enzyme than currently marketed enzyme replacement therapies for Fabry disease.
PLX: 2.23 (+0.01)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:15AM CST

NRX: 8.26 (-0.08), BIND: 6.84 (-0.33), NBG: 1.23 (+0.06), MBT: 11.97 (+0.18), STML: 16.58 (-0.42), BIOD: 1.14 (-0.13), SIG: 138.00 (+0.02), PBR: 9.99 (+0.59), NBIX: 43.37 (-0.31), PIR: 13.29 (+0.23), VLCCF: 5.00 (unch), CONN: 30.85 (+0.15), CYTR: 5.13 (-0.13), PLX: 2.23 (+0.01), MEET: 1.78 (+0.03), INFI: 14.54 (-0.11), CYRN: 3.24 (+0.01), APOL: 17.51 (-0.40), CJJD: 4.01 (+0.27), CRK: 4.63 (-0.04), FOLD: 12.25 (-0.05), GST: 3.30 (-0.04)

Protalix BioTherapeutics Reports Positive Interim Data From Phase I/II Clinical Trial of PRX-102 for the Treatment of Fabry Disease
GlobeNewswire - Thu Jan 08, 6:12AM CST
Meaningful Clinical Benefits Demonstrated Across All Key Disease Parameters
PLX: 2.23 (+0.01)

Protalix BioTherapeutics, Inc. (PLX) Jumps: Stock Rises 16% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 8:32AM CST
Protalix BioTherapeutics, Inc. (PLX) was a big mover last session, as the company saw its shares rise more than 16% on the day.
PLX: 2.23 (+0.01), AFFX: 12.44 (-0.16)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 11:48AM CST

SD: 1.84 (unch), XENT: 25.91 (-0.24), WLL: 35.62 (-1.01), BTE: 19.52 (+0.11), BOTA: 2.41 (+0.08), CNAT: 6.66 (-0.15), WG: 2.61 (-0.15), SN: 13.58 (-0.05), LPI: 14.72 (-0.32), EROC: 2.55 (+0.03), BCLI: 4.14 (+0.02), NDRM: 13.61 (-0.14), SMLR: 3.75 (+0.34), QURE: 26.09 (-0.28), SFY: 2.91 (-0.07), ANTH: 5.20 (+0.31), PLX: 2.23 (+0.01), APRI: 1.61 (-0.13), STXS: 2.15 (-0.09), GST: 3.30 (-0.04)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duke Energy's $500K Push Against South Carolina Hunger

A Battle Cry Against Hunger Look, there’s no shortage of firms tossing around cash as PR stunts. But Duke Energy’s latest campaign to tackle hunger in South Carolina right at the root is one effort that seems to echo with a real bang. Coming at us with more than $500,000 in support for nearly 70 organizations across the state, they’re not just talking the talk. This...

Dahua Technology Showcases Smart City AI at SCEWC 2026

AIoT Innovations Unveiled at SCEWC 2026 Once in a while, something comes along that makes you sit up and pay attention, and this time it's Dahua Technology. Picture a sprawling metropolis where smart tech not only keeps the wheels turning but actually makes life better. That's the ambition Dahua laid out during the Smart City Expo World Congress 2026 in Barcelona,...

Extra Space Storage Declares Q4 2026 Dividend

Sizing Up Extra Space Storage's Dividend Declaration Well, here's a tidbit that might not shake your morning coffee off the table, but still worth a glance. Extra Space Storage Inc. (NYSE: EXR) tossed out news that its board has given the go-ahead for a heftier-than-you-might-expect $1.62 per share dividend for the fourth quarter of 2026. Now, that's not chump change!...

BDX Flexes Financial Muscle with Strong FY26 Results

BD's Performance in FY2026: A Strong Finish Y'know, it's not every day we see a giant like Becton, Dickinson and Company (NYSE: BDX) grinding out some impressive numbers. But, here we are. They just wrapped up fiscal 2026, and it's looking like they ain't just skating by. We're talking a 5.4% bump in fourth quarter revenue, landing them at a cool $5.3 billion. Not too...

Pye-Barker's Bold Play in Florida Fire Safety Market

A Strategic Spark in Fire Protection Well, here's a move that lights up the fire protection sector. Pye-Barker Fire & Safety, known for being the top dog in U.S. fire safety services, decided to scoop up St. John's Fire Equipment down in Florida. Let's just say, they're not putting out any fires here—more like stoking a strategic blaze. This acquisition positions...

PulseAI's AI-Driven Wearable Clears FDA Hurdle

PulseAI Breaks Ground in Wearable Cardiac Monitoring The news is out, folks. PulseAI, a medical tech up-and-comer, has sealed the deal with an FDA 510(k) clearance for its AI-driven arrhythmia analysis for wearables. That's a bureaucratic mouthful, but what it boils down to is this: we're looking at huge potential in wearable tech improving cardiac healthcare. With...

EWTN Broadcasts Pope Leo XIV's Latin America Visit Live

Pope Leo XIV Embarks on Landmark Latin America Tour While Wall Street rumbles its daily tune, I've got my eyes on a different spectacle: Pope Leo XIV making rounds in South America from November 6 to 17. This isn't your typical news peg. This stretches beyond financial chatter into a spectacle of faith and cultural resonance. No price charts to weave here, just the...

Sabre's Q3 Earnings: What Investors Need to Know

Unpacking Sabre's Latest Financial Reveal Sabre Corporation, that familiar name in travel tech, let the third quarter numbers out of the bag. Published fresh off the wire on November 5th, this round of figures covers the books up until September 30, 2026. If you're wired into NASDAQ:SABR, this is your bread and butter for the quarter. The figures, straight from Sabre's...

WebAI Debuts Mac App for On-Device AI Prowess

WebAI Breaks the Cloud AI Mold Listen, the tech landscape just got a little more interesting. With webAI's latest move, the game has shifted for those who live and breathe AI but aren't keen on their files dancing across the internet. Their new Mac app lets you run AI models without the cloud's watchful eye—or its per-token charges. Finally, some privacy in this digital...

Digging Deep: How Excavation Preps Before the First Shovel

Laying the Groundwork Before Breaking Any Ground When it comes to excavation, it's not just about firing up the heavy machinery and hoping for the best. There's a whole lot of groundwork—pun definitely intended—that goes into prepping a site before any actual digging begins. Kenneth Zittel, an Excavation Expert, gives us the lowdown on how it’s done, and let me tell...